Introduction
============

With increasing international travel across countries, including those in malaria-endemic regions, and the continued spread of resistance to antimalarial drugs, travelers are at risk for contracting malaria.[@b1-dhps-4-087] Travelers who are naturally vulnerable because of lowered immunity, such as young children, people with chronic diseases, elderly people, and pregnant women, now travel more frequently; consequently, imported malaria is observed more often in these subgroups.[@b2-dhps-4-087],[@b3-dhps-4-087] Although imported malaria is preventable, many travelers fail to use or comply with appropriate chemoprophylaxis due to concerns regarding side effects associated with antimalarial chemoprophylaxis.[@b4-dhps-4-087]

There is a consensus that the ideal chemoprophylactic medication should be highly effective, cause few or no adverse events (AEs), be appropriate for all travelers, including pregnant women, nursing mothers, small children, long-term travelers, should be cheap and easy to use and should be registered globally for this indication.[@b5-dhps-4-087] An AE is classified as "any undesirable medical occurrence that develops after the administration of a drug, regardless of the suspected relationship between the drug product and the event". In order to classify an event as an adverse drug reaction (ADR), a causal relationship must be established.[@b6-dhps-4-087],[@b7-dhps-4-087] In the present analysis, a serious adverse event (SAE) was defined as any adverse experience that resulted in death, a life-threatening experience, participant hospitalization, or persistent or significant disability or incapacity. We also examined specific medical or surgical intervention to prevent serious outcomes.[@b8-dhps-4-087],[@b9-dhps-4-087]

Currently, three main antimalarial drugs, atovaquone-proguanil, doxycycline, and mefloquine (MFQ), are used as chemoprophylaxis for those traveling to regions with known chloroquine-resistant *Plasmodium falciparum* malaria.[@b4-dhps-4-087]

MFQ has been available for malaria chemoprophylaxis since 1985 in Europe and since 1990 in the USA.[@b5-dhps-4-087] Due to the drug's characteristics of schizontocidal action against the blood stages of all human malaria species including *P. knowlesi*,[@b10-dhps-4-087] its affordability, and because it is administered once weekly resulting in good adherence, MFQ is an effective malaria chemoprophylaxis for travelers going to high risk chloroquine-resistant *P. falciparum* areas[@b5-dhps-4-087] in the Thai border regions known to have multidrug resistance.[@b5-dhps-4-087] To date, the drug is used clinically as a 50:50 racemic mixture of the erythro isomers and all clinical studies involving this drug have used this mixture.[@b5-dhps-4-087]

The Cochrane systematic review incorporated eight randomized controlled trials (RCTs) with 4240 participants to assess currently used antimalarial drugs including MFQ for chemoprophylaxis of malaria in travelers. In the review, no SAEs were reported.[@b4-dhps-4-087] Overall, pregnant women who took MFQ at various doses for both prevention and treatment of malaria did not have an increased risk of teratogenic effects (birth defects) or adverse pregnancy outcomes compared to the background rate in the general population.[@b11-dhps-4-087] In contrast, the risk of AEs, particularly neuropsychiatric AEs, related to the prophylactic use of MFQ, has also been reported,[@b1-dhps-4-087] which adversely affects compliance[@b12-dhps-4-087] or may result in switching to less-effective alternatives. Studies have also identified severe psychiatric side effects related to the use of MFQ in preventing malaria.[@b13-dhps-4-087],[@b14-dhps-4-087] A study involving US military personnel deployed to Afghanistan reported that approximately one in seven individuals with neuropsychiatric contraindications received a prescription for MFQ prior to combat deployment.[@b15-dhps-4-087] Thus, from the aspect of patient safety, potential harm to the prospective users must be identified.

Pharmacovigilance is defined as "the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug related problem".[@b6-dhps-4-087],[@b9-dhps-4-087] Two broad approaches for pharmacovigilance are used in developed countries, including passive spontaneous reporting systems and systems utilizing pharmacoepidemiological methods.[@b7-dhps-4-087],[@b16-dhps-4-087] The latter approach can be applied to data from clinical trials if the sample size is adequate to assess risks in multiple arm treatments and if the collection of safety data is standardized to ensure high quality.[@b7-dhps-4-087]

Materials and methods
=====================

Study objective
---------------

The aim of the present study was to identify signals of SAEs resulting from the use of MFQ based on data from clinicoepidemiological studies.

Data source
-----------

In order to illustrate the signal detection for identifying SAEs in travelers taking MFQ for chemoprophylaxis, data from two sources, an individual study and the pooled data of RCTs, were extracted. We collected AE-related data from published studies and from a Cochrane systematic review. The data were from the empirical studies rather than that submitted by physicians, pharmacists, other health care professionals, manufacturers, or consumers. However, these data could be regarded as being spontaneously reported AEs by researchers because they (i) highlight the disproportionality, (ii) allow for estimation of relative risks, (iii) can give rise to less bias than case reports, and (iv) are available for calculations of disproportionality based upon presentation in a 2 × 2 contingency table. In order to reflect the spontaneous reporting manner, we collected data according to the year the study was conducted. If duplicate reports for the same patient but from different sources were noted, only the latest updated data were included.

Clinical judgment was applied to identify neuropsychiatric events as defined by the medical dictionary for regulatory activities preferred terms ([Table 1](#t1-dhps-4-087){ref-type="table"}).[@b17-dhps-4-087]

Data analyses
-------------

The association between antimalarial drugs, including MFQ, and neuropsychiatric events was analyzed using the reporting odds ratio (ROR) and corresponding 95% confidence interval (CI) data-mining algorithm. ROR values for MFQ denote the ratio of the observed to the expected number of reported neuropsychiatric events compared with other antimalarial drugs in the data set during the analysis period. Values less than 1 indicate no exposure-event association, while values greater than 1 indicate exposure-event safety signals. From the regulatory science perspective, safety signals are considered significant when the ROR estimates and the lower limits of the corresponding 95% CI are ≥2.[@b18-dhps-4-087]

[Table 2](#t2-dhps-4-087){ref-type="table"} shows the data-mining algorithm to calculate point estimates of ROR and the corresponding 95% CI for MFQ and comparators in the study. Data entry and analyses were performed using a Microsoft Excel (Microsoft, Redmond, WA) spreadsheet.

Results
=======

Two data sets were identified for this analysis. The Barrett data[@b19-dhps-4-087] compared MFQ and a combination drug of chloroquine and proguanil. The Cochrane database[@b4-dhps-4-087] assessed multiple comparisons including MFQ, atovaquone-proguanil, and doxycycline. Regarding the source of data collection, the former was from a retrospective survey (n = 1214 adults), while the latter was from eight RCTs (n = 4240 adults). The distribution of SAEs in travelers taking MFQ as a chemoprophylaxis and the respective data sources[@b19-dhps-4-087]--[@b22-dhps-4-087] are shown in [Tables 3](#t3-dhps-4-087){ref-type="table"} and [4](#t4-dhps-4-087){ref-type="table"}.

Based on our estimates from of the two database sources, the estimated RORs and their corresponding 95% CI data-mining algorithm for MFQ are presented in [Tables 5](#t5-dhps-4-087){ref-type="table"} and [6](#t6-dhps-4-087){ref-type="table"}. In both data sources, ROR values with low 95% CI values were less than 2. This indicates that signals for SAE pertinent to neuropsychiatric events were not detected.

Discussion
==========

For all medications, there is a trade-off between the benefits and the potential for harm; these factors should be analyzed and communicated effectively as part of an effective approach towards pharmacovigilance.[@b6-dhps-4-087] Anecdotal reports can identify the occurrence of an AE that may be coincidental[@b23-dhps-4-087] rather than actual harm. It is important for patient safety to detect drug-event combinations and analyze these events using appropriate statistical methods.[@b24-dhps-4-087],[@b25-dhps-4-087] The present study provides information regarding the safety level of MFQ in adult travelers in the context of pharmacovigilance. As the ROR estimates and the lower limits of the corresponding 95% CI were \<2 in both database sources in the present analysis, a safety signal was not detected.

Upon comparison of MFQ with the single comparator quinine or a combination drug (ie, chloroquine plus proguanil) in the present analysis, "signal dilution"[@b26-dhps-4-087] was not observed. As data collection is expensive, data-mining processes are often performed using existing databases for the purpose of pharmacovigilance.[@b6-dhps-4-087],[@b27-dhps-4-087] Regarding the methodology of the data-mining process, measures of disproportionality are the only techniques which have been used to identify AEs.[@b27-dhps-4-087] The current analysis followed this approach as well.

Spontaneous reporting to the World Health Organization or to the Food and Drug Administration may provide data on a broad spectrum of patients. Moreover, ADRs that occur after prolonged exposure or ADRs that are extremely rare can be detected through spontaneous reports. However, the absence of a control group and the lack of a denominator indicate that the attributable rate of the ADR cannot be calculated.[@b28-dhps-4-087] Case reports are the main source of information used to withdraw a drug from the market for safety reasons.[@b29-dhps-4-087] In assessing the culprit drug, it is difficult to determine whether the report is a genuine alert or a false alarm.[@b30-dhps-4-087] The aim of the present study was not to examine the reporting system, but to highlight the usefulness of other published data sources for signal detection.

The risk of malaria during travel is determined by immunological characteristics of the individual traveler (the person), the travel destination (the place), and the use of preventive anti-mosquito measures and adequate chemoprophylaxis (prevention without and with drugs).[@b4-dhps-4-087] In the present study, based on two different data sources, signals for neuropsychiatric event were not detected. Importantly, if a signal is not detected, it is impossible to determine whether no AEs (neuropsychiatric event in our case) exist or whether the data are insufficient.[@b27-dhps-4-087] Further studies are needed to substantiate this hypothesis. Nevertheless, as our data pertinent to the second database were rooted in RCTs, our estimation of signal detection is less likely to exhibit bias. Additionally, approximately one in seven individuals with neuropsychiatric contraindications received a prescription for MFQ prior to combat deployment.[@b15-dhps-4-087] Travelers and the deployment groups cannot necessarily be equated. Deployment may result in psychiatric casualties that are either the result of inadequate coping with deployment stressors or acute stress reactions caused by battle trauma or combat stress reactions.[@b31-dhps-4-087] Stress-inducing factors compounded to the effect of MFQ may be a likely cause of neuropsychiatric events in this population. In pharmacovigilance and in medicine in general, it is important to be cognizant of interactions, not only between drugs but also between drugs and diseases as well as environmental factors. As such, nondrug interactions may act as confounders when they are actually co-precipitating factors[@b25-dhps-4-087] in this special population.

We were unable to identify a signal for detection based on two datasets in which study time and participants were not the same. Thus, whether drug-events were related to MFQ-related neuropsychiatric effects did not vary significantly over time. Second, there was a relatively higher frequency of neuropsychiatric AEs related to MFQ than to comparator drugs although they were not related to SAEs. This highlights the need for clinical surveillance of MFQ chemoprophylaxis with stratification by gender or age group.

Notably, no individual approach to detect signals (ROR in our case) is adequate and the concurrent use of other methods is therefore essential.[@b32-dhps-4-087] Further incorporation of pharmacovigilance principles into clinical practice and academic medicine is necessary.[@b6-dhps-4-087] As such, published studies have postulated that neurologic syndromes in patients induced by MFQ were likely due to a central anticholinergic syndrome.[@b32-dhps-4-087] Although multiple factors may have contributed to cognitive impairment, the temporal relationship between symptom onset and MFQ use suggests a high likelihood that MFQ was the causal factor;[@b33-dhps-4-087] hence, further studies are warranted. There may be important differences between the pharmacokinetic properties of MFQ in pregnancy and nonpregnant adults.[@b34-dhps-4-087] Moreover, we recommend future studies assessing SAE of MFQ for preventing malaria in pregnant women.
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###### 

Selected MedDRA preferred terms that reflect neuropsychiatric events

  Category                           Preferred terms
  ---------------------------------- --------------------------------
  Delirium                           Delirium
  Delirium febrile                   
  Delusions/perceptual disturbance   Delusion
  Delusional perception              
  Hallucination                      
  Hallucination, auditory            
  Hallucination, visual              
  Hallucinations, mixed              
  Illusion                           
  Paranoia                           
  Suicidal events                    Completed suicide
  Self-injurious behavior            
  Self-injurious ideation            
  Suicidal ideation                  
  Suicide attempt                    
  Convulsion                         Grand mal convulsion
  Clonic convulsion                  
  Convulsion                         
  Epilepsy                           
  Febrile convulsion                 
  Partial seizures                   
  Status epilepticus                 
  Tonic convulsion                   
  Depressed level of consciousness   Altered state of consciousness
  Consciousness fluctuating          
  Depressed level of consciousness   
  Abnormal behavior                  Abnormal behavior

**Note:** Each term category has multiple verbatim terms identified.

**Abbreviation:** MedDRA, Medical Dictionary for Regulatory Activities.

###### 

The 2 × 2 contingency table used for calculating reporting odds ratios and 95% CI data-mining algorithm

  Exposure                                             Neuropsychiatric events   Other AEs   Total
  ---------------------------------------------------- ------------------------- ----------- -------
  Mefloquine                                           A                         B           A + B
  Other antimalarial drugs                             C                         D           C + D
  Total                                                A + C                     B + D       N
  ROR: [A/B]{.ul}                                                                            
  C/D                                                                                        
  95% CI: e ^ln(ROR)\ ±\ 1.96\ √1/A\ +\ 1/B\ +\ 1/C^                                         

**Abbreviations:** AE, adverse event; ROR, reporting odds ratio.

###### 

Distribution of adverse events in travelers taking mefloquine chemoprophylaxis

  Adverse events        Reported serious AE   Remarks   
  --------------------- --------------------- --------- ---------------
  Nervous system AE     31                    12        Serious AE
  GI-related AE         26                    16        Nonserious AE
  Other nonserious AE   20                    19        Nonserious AE

**Notes:** Derived from data in Barretts et al.[@b19-dhps-4-087]

**Abbreviations:** AE, adverse event; GI, gastrointestinal symptoms; MFQ, mefloquine.

###### 

Distribution of serious adverse events in preventing malaria in travelers

  Study reference no   Year of publication   MFQ   Comparator                                      Adverse events
  -------------------- --------------------- ----- ----------------------------------------------- ---------------------------
  [@b20-dhps-4-087]    2003                  36    34[a](#tfn7-dhps-4-087){ref-type="table-fn"}    Dermatological reaction
  [@b1-dhps-4-087]     2001                  15    12[a](#tfn7-dhps-4-087){ref-type="table-fn"}    Do
  [@b20-dhps-4-087]    2003                  89    88[a](#tfn7-dhps-4-087){ref-type="table-fn"}    Gastrointestinal symptoms
  [@b1-dhps-4-087]     2001                  94    77[a](#tfn7-dhps-4-087){ref-type="table-fn"}    Gastrointestinal symptoms
  [@b20-dhps-4-087]    2003                  118   109[a](#tfn7-dhps-4-087){ref-type="table-fn"}   Neuropsychiatric
  [@b1-dhps-4-087]     2001                  139   69[a](#tfn7-dhps-4-087){ref-type="table-fn"}    Do
  [@b1-dhps-4-087]     2001                  10    4[a](#tfn7-dhps-4-087){ref-type="table-fn"}     Serious adverse events
  [@b20-dhps-4-087]    2003                  0     0[a](#tfn7-dhps-4-087){ref-type="table-fn"}     Do
  [@b21-dhps-4-087]    1997                  22    22[b](#tfn8-dhps-4-087){ref-type="table-fn"}    Dermatological reaction
  [@b20-dhps-4-087]    2003                  45    42[b](#tfn8-dhps-4-087){ref-type="table-fn"}    Do
  [@b21-dhps-4-087]    1997                  29    16[b](#tfn8-dhps-4-087){ref-type="table-fn"}    Gastrointestinal symptoms
  [@b20-dhps-4-087]    2003                  89    81[b](#tfn8-dhps-4-087){ref-type="table-fn"}    Do
  [@b22-dhps-4-087]    1990                  64    58[b](#tfn8-dhps-4-087){ref-type="table-fn"}    Do
  [@b20-dhps-4-087]    1997                  38    22[b](#tfn8-dhps-4-087){ref-type="table-fn"}    Neuropsychiatric
  [@b1-dhps-4-087]     2003                  118   115[b](#tfn8-dhps-4-087){ref-type="table-fn"}   Do
  [@b22-dhps-4-087]    1990                  10    6[b](#tfn8-dhps-4-087){ref-type="table-fn"}     Do

**Notes:**

Comparator is atovaquone-proguanil;

comparator is doxycycline. Derived from primary studies included in Jacquerioz and Croft.[@b4-dhps-4-087]

**Abbreviation:** MFQ, mefloquine.

###### 

Reporting odds ratio and 95% CI data-mining algorithm for mefloquine alone

  Exposure                   Neuropsychiatric events   Other AEs   Total
  -------------------------- ------------------------- ----------- -------
  Mefloquine                 31                        46          77
  Other antimalarial drugs   12                        35          47
  Total                      43                        81          124
  ROR: [A/B]{.ul}            1.58                                  
  C/D                                                              
  95% CI                     1.49--1.68                            

**Note:** Data derived from [Table 3](#t3-dhps-4-087){ref-type="table"}.

**Abbreviations:** AE, adverse event; CI, confidence interval; ROR, reporting odds ratio.

###### 

Reporting odds ratio and 95% CI data-mining algorithm for mefloquine in travelers

                       Neuropsychiatric   Others AE[a](#tfn13-dhps-4-087){ref-type="table-fn"}
  -------------------- ------------------ ------------------------------------------------------
  Mefloquine           257                286
  Other antimalarial   200                266
  ROR: [A/C]{.ul}      1.195              
  B/D                                     
  95% CI               0.94--1.44         

**Notes:** Data derived from [Table 4](#t4-dhps-4-087){ref-type="table"};

focusing on gastrointestinal symptoms.

**Abbreviation:** AE, adverse event; CI, confidence interval; ROR, reporting odds ratio.
